Anti-inflammatory agent 112

Anti-inflammatory agent 112 (compound 3f) (1-10 μM; 48 h) maintains over 90% cell viability in RAW264.7 macrophages^[1].
Anti-inflammatory agent 112 (compound 3f) (1-10 μM; 1 h pre-treatment before 24 h LPS stimulation) inhibits LPS-induced NO production in RAW264.7 macrophages with 54.3% inhibition at 10 μM, acting in a concentration-dependent manner^[1].
Anti-inflammatory agent 112 (1-10 μM; pre-treated before 24 h LPS induction) significantly reduces LPS-induced IL-6 and TNF-α release in RAW264.7 macrophages, with a concentration-dependent effect^[1].
Anti-inflammatory agent 112 (5-10 μM; 1 h pre-treatment before 24 h LPS stimulation) suppresses LPS-induced i-NOS and COX-2 protein expression in RAW264.7 macrophages^[1].
Anti-inflammatory agent 112 binds to 1DD7, 1NFK, 2Z64, and 5COX with binding energies ranging from -5.16 to -9.17 kcal/mol, showing favorable interactions with most targets compared to compound 3d^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.